BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 20452168)

  • 1. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
    Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study.
    Pessaux P; Marzano E; Casnedi S; Bachellier P; Jaeck D; Chenard MP
    World J Surg; 2010 Nov; 34(11):2765-72. PubMed ID: 20652697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.
    Nakano H; Oussoultzoglou E; Rosso E; Casnedi S; Chenard-Neu MP; Dufour P; Bachellier P; Jaeck D
    Ann Surg; 2008 Jan; 247(1):118-24. PubMed ID: 18156931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases.
    Kandutsch S; Klinger M; Hacker S; Wrba F; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2008 Nov; 34(11):1231-6. PubMed ID: 18272318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
    J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
    Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
    Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
    Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
    Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients.
    Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR
    Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
    Komori H; Beppu T; Baba Y; Horino K; Imsung C; Masuda T; Hayashi H; Okabe H; Ootao R; Watanabe M; Takamori H; Iyama K; Baba H
    Int J Clin Oncol; 2010 Jun; 15(3):263-70. PubMed ID: 20238233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved first-line chemotherapy: a better chance for surgery?
    Tejpar S; Van Cutsem E; Adam R
    Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480
    [No Abstract]   [Full Text] [Related]  

  • 14. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
    Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
    Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
    Boxberger F; Albrecht H; Konturek PC; Reulbach U; Maennlein G; Meyer T; Hohenberger W; Hahn EG; Wein A
    Med Sci Monit; 2010 Feb; 16(2):CR49-55. PubMed ID: 20110914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
    Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
    Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
    Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
    Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.